🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

SCYNEXIS, Inc. SCYX PHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.scynexis.com
Company Profile ↓
$5.15
-23.82% 1Y
Mkt Cap$51.24M
P/E-5.66
P/B0.66
52W High$9.44
52W Low$3.57
Book Value$6.73
EPS (TTM)$-0.91

Company Overview

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Recent Developments

  • Dec 2025 Revenue of $20.60M (+449.9% YoY); net profit $-8.61M.
  • Trailing 12 Months Year-on-year growth — revenue -82.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.84%
1 Year:-82.80%

Stock Price Performance

1 Year:-23.82%
6 Months:-25.15%
3 Months:+15.73%
1 Month:-1.72%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 27% of range
$3.57 $9.44
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)51.56 · Neutral
Price Performance
1M-1.72%
3M+15.73%
6M-25.15%
1Y-23.82%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 45.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-5.66
Industry PE
24.83
Forward P/E
-2.22
PEG Ratio
-
Book Value
$6.73
Price to Book
0.66
P/S
2.31
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
1.84%
Profit 5Y
-
Revenue (YoY)
-82.80%
Earnings (YoY)
-

Profitability & Returns

ROCE
-30.16%
ROE
-18.38%
ROA
-20.82%
Profit Margin
-53.26%
Op Margin
-
Gross Margin
100.00%
EPS (Latest Qtr)
$-3.36
EPS (TTM)
$-0.91

Balance Sheet & Liquidity

Debt/Equity
2.91
Quick Ratio
9.29
Current Ratio
9.65
Debt
$1.95M
Total Assets
$77.63M
Current Assets
$62.69M
Working Capital
$34.64M

Ownership

Promoter Holding
1.99%
Chg in Prom Hold
-0.00%
FII / Inst Holding
61.95%
Chg in FII Hold
8.98%

Financial Snapshot

Enterprise Value
$51.24M
Total Revenue (TTM)
$19.22M
EBITDA
$-8.44M
Free Cash Flow
$-7.32M
Operating Cash Flow
$-13.31M
Shares Outstanding
9.95M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SCYX SCYNEXIS, Inc. PHARMA 5.15 -5.66 $51.24M 0.00% -30.16% -18.38% 1.84% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------64.00K64.00K64.00K64.00K64.00K64.00K57.00K000012.05M0516.00K687.00K1.32M1.56M1.13M131.45M1.76M1.37M736.00K660.00K-257.00K1.36M334.00K18.65M0
Cost of Revenue ----------------------------------0-----
Gross Profit 462.00K720.00K66.00K-------------------------------977.00K-----
Operating Expenses -----------------------------------8.87M10.93M8.74M8.12M16.94M
Operating Income -4.01M-4.54M-5.93M-6.49M-7.54M-8.39M-7.21M-8.27M-6.71M-5.63M-6.02M-6.75M-6.40M-7.23M-7.66M-6.30M-11.86M-11.20M-11.76M-12.48M-11.83M-11.51M-1.59M-17.51M-19.44M-19.74M-21.74M-21.80M-10.68M116.51M-10.10M-9.51M-9.24M-10.32M--8.61M-9.56M-8.40M10.52M-16.94M
EBITDA ------------------------------------5.22M-6.88M-8.59M12.26M-21.30M
Interest Expense -----------------------------------173.00K0000
Pretax Income ------------------------------------5.39M-6.88M-8.59M12.26M-21.30M
Tax Provision ----------------------------------23.00K0000-
Net Income 2.23M-3.80M-6.38M-9.50M-8.36M--7.18M-8.13M-11.23M--4.87M-4.20M-8.40M-4.00M-10.76M351.00K-22.91M-8.40M-7.94M-7.00M-6.38M909.00K-4.68M1.66M-605.00K-5.45M-13.35M-29.58M-33.88M122.26M-1.76M411.00K-14.46M-2.81M--5.39M-6.88M-8.59M12.26M-21.30M
Diluted EPS -0.98-0.45-0.75-0.78-0.60--0.52----0.25--0.31-0.12-0.01---1.45-0.72-0.64-0.28-0.23-0.22-0.06-0.18-0.31-0.62-0.712.46-0.040.01-0.30-0.06--0.88-1.12-1.36--3.36
R&D Expense 1.82M2.48M3.79M3.28M3.46M-4.74M6.66M4.89M-4.02M4.45M4.46M5.33M5.60M3.93M9.68M8.47M9.28M9.87M8.47M8.03M6.95M4.73M4.40M5.74M7.13M6.43M6.83M7.04M6.47M7.21M6.81M8.07M-5.14M7.14M5.45M-12.35M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 16.86M1.26M257.00K257.00K257.00K257.00K121.00K0-5.09M140.14M3.75M20.60M
Cost of Revenue --------312.00K628.00K15.62M0-
Gross Profit 552.00K3.58M------12.85M4.46M124.52M3.75M-
Operating Expenses ---------90.22M51.85M40.86M36.67M
Operating Income -7.20M-14.65M-28.35M-27.82M-26.32M-29.98M-48.92M-51.15M--85.76M72.67M-37.12M-16.07M
EBITDA ----------61.70M70.89M-20.31M-8.44M
Interest Expense ---------5.20M3.13M828.00K173.00K
Pretax Income ----------67.51M67.18M-21.14M-8.61M
Tax Provision ----------4.70M138.00K151.00K0
Net Income -46.81M-5.87M-32.62M-29.99M-25.06M-12.47M-53.71M-55.19M--62.81M67.04M-21.29M-8.61M
Diluted EPS -139.47-2.69-2.68-1.58------11.7611.12-3.52-1.36
R&D Expense 4.36M8.29M16.44M20.08M18.33M21.56M38.39M36.52M23.77M27.26M30.93M26.41M22.28M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -12.39M39.67M49.27M59.79M45.85M53.17M57.15M102.54M-87.81M128.41M90.64M59.03M
Current Assets ----------79.06M102.12M72.18M40.37M
Cash & Equivalents 2.38M1.40M32.24M46.98M35.66M11.47M11.44M41.92M93.04M-45.81M34.05M16.05M21.26M
Inventory ---------463.00K899.00K0--
Receivables ---------861.00K2.10M0--
Total Liabilities -33.34M6.24M7.32M24.97M24.44M21.95M44.26M79.78M-84.58M55.45M35.57M9.65M
Current Liabilities -18.48M5.35M6.66M3.72M10.14M5.88M11.01M26.40M-17.62M16.30M24.10M5.73M
Long Term Debt ---014.25M10.30M15.08M0-40.35M45.39M12.16M--
Total Debt ----------48.60M15.08M16.27M2.17M
Total Equity -65.42M-108.11M33.43M41.95M34.82M21.41M31.23M12.89M22.76M-3.23M72.96M55.08M49.38M
Shares Outstanding ----------4.09M4.65M4.75M5.44M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --9.47M-24.55M-29.35M-24.56M-28.32M-38.12M-49.35M--79.88M60.16M-24.01M-5.28M
Investing Cash Flow --488.00K1.59M-22.47M-9.62M-803.00K26.24M6.47M--27.39M-34.88M6.15M24.31M
Financing Cash Flow -40.80M37.70M40.50M9.99M29.42M42.30M94.00M-48.60M-36.72M-139.00K-14.17M
Capital Expenditure -431.00K-704.00K-589.00K-27.00K-2.00K-565.00K-0-4.00K-1.17M-9.00K---
Free Cash Flow --10.18M-25.13M-29.38M-24.56M-28.89M-38.12M-49.36M--79.89M60.16M-24.01M-5.28M
Net Change in Cash ----------58.67M-11.44M-18.00M4.85M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 3.3%284.9%-------87.7%88.9%100.0%-
Operating Margin % -42.7%-1,166.2%-11,030.7%-10,823.7%-10,241.2%-11,666.5%-40,430.6%---1,684.5%51.9%-990.8%-78.0%
Net Margin % -277.7%-467.1%-12,693.8%-11,668.9%-9,751.0%-4,851.4%-44,388.4%---1,233.7%47.8%-568.3%-41.8%
ROE % 43.3%-17.5%-77.8%-86.1%-117.0%-39.9%-416.5%-242.5%--1,942.7%91.9%-38.7%-17.4%
ROCE % 118.3%-42.7%-66.5%-49.6%-73.7%-63.4%-106.0%-67.2%--122.2%64.8%-55.8%-30.2%

Shareholding Pattern

Insiders
1.99%
Institutions
61.95%
Public Float
63.21%

Top Institutional Holders

#Holder% HeldSharesValue
1 Great Point Partners LLC 9.49% 944.29K $4.21M
2 Squadron Capital Management LLC 7.61% 756.88K $3.38M
3 Propel Bio Management, LLC 5.46% 543.48K $2.42M
4 Adage Capital Partners GP L.L.C. 5.46% 543.48K $2.42M
5 Woodline Partners LP 3.89% 387.52K $1.73M
6 Vanguard Capital Management LLC 2.98% 296.75K $1.32M
7 Avidity Partners Management, LP 2.62% 260.21K $1.16M
8 Kingdon Capital Management LLC 2.49% 247.81K $1.11M
9 Millennium Management Llc 1.82% 180.79K $806.31K
10 Heights Capital Management, Inc 1.51% 150.55K $671.46K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SCYX

Yahoo Finance ue, 01 Sep 2026

SCYNEXIS to Participate in Upcoming Investor Conferences

JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical…

Yahoo Finance Mon, 10 Aug 2026

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2 study The Phase 2 pro…

Yahoo Finance ue, 30 Jun 2026

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnol…

Yahoo Finance Fri, 22 May 2026

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advanci…

Yahoo Finance Mon, 11 May 2026

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase 2 proof-of-concept study of SCY-770 in A…

Yahoo Finance hu, 07 May 2026

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Au…

SCYX — Frequently Asked Questions

What is the current share price of SCYNEXIS, Inc. (SCYX)?

As of 2026-09-19 21:16 PDT, SCYNEXIS, Inc. (SCYX) trades at $5.15 on NasdaqCM. Its 52-week range is $3.57 to $9.44.

What is the market capitalisation of SCYX?

SCYNEXIS, Inc. (SCYX) has a market capitalisation of $51.24M on NasdaqCM.

What is the P/E ratio of SCYX?

SCYX trades at a trailing price-to-earnings (P/E) ratio of -5.66. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.66.

What is the return on equity (ROE) of SCYX?

SCYX has a return on equity (ROE) of -18.38%. Its return on capital employed (ROCE) is -30.16%.

Is SCYX a good stock to buy?

This page provides a data-driven analysis of SCYNEXIS, Inc. (SCYX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space